Alto Neuroscience (NYSE:ANRO) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Alto Neuroscience's stock has been given a Sell (D-) rating by Weiss Ratings, reflecting concerns over the company's performance.
• HC Wainwright and Chardan Capital have provided contrasting evaluations, with HC Wainwright maintaining a buy rating and a target price of $10.00, while Chardan Capital also rates it a buy with a target of $15.00.
• The company reported a loss of ($0.65) earnings per share for the last quarter, missing analysts' expectations of ($0.57) by a margin of $0.08.

Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently commented on ANRO. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Alto Neuroscience in a report on Monday, August 18th. Chardan Capital started coverage on shares of Alto Neuroscience in a report on Monday, September 29th. They set a "buy" rating and a $15.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $9.80.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded up $0.28 during midday trading on Wednesday, hitting $6.22. The company's stock had a trading volume of 379,606 shares, compared to its average volume of 567,491. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $15.04. The firm's fifty day moving average price is $3.80 and its 200-day moving average price is $2.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The firm has a market cap of $168.44 million, a P/E ratio of -2.60 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08). On average, sell-side analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several large investors have recently modified their holdings of ANRO. Armistice Capital LLC boosted its holdings in shares of Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock worth $3,456,000 after buying an additional 950,000 shares during the period. Peapod Lane Capital LLC bought a new stake in Alto Neuroscience in the 2nd quarter valued at $613,000. AWM Investment Company Inc. boosted its holdings in Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock valued at $1,948,000 after purchasing an additional 214,153 shares during the period. Nuveen LLC bought a new stake in Alto Neuroscience in the 1st quarter valued at $302,000. Finally, Jane Street Group LLC bought a new stake in Alto Neuroscience in the 2nd quarter valued at $240,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.